For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Asifa Akhtar obtained her bachelors degree in biology at University College London (UCL) in 1993. This was followed by her PhD in 1998 from the Imperial Cancer Research Fund in London, where she studied transcription regulation in Richard Treisman’s laboratory. She continued in the field of chromatin regulation as a postdoctoral fellow at the European Molecular Biology Laboratory (EMBL), Heidelberg and the Adolf Butenandt Institute, Munich in Peter Becker’s laboratory until 2001.
From 2001, she led her own research as a group leader at EMBL. In 2009, her laboratory moved to the Max Planck Institute of Immunobiology and Epigenetics, Freiburg. She is currently managing director at the Max Planck Institute of Immunobiology and Epigenetics and is heading the department of chromatin regulation. Her laboratory primarily studies chromatin and epigenetic mechanisms, especially focusing on the regulation of the X chromosome by the phenomenon of dosage compensation in Drosophila melanogaster.
In 2008, she received the European Life Science Organization (ELSO) award for significant contribution in the field and in 2013 she was elected as an EMBO member.
I was always interested in biology, but if I think back to when I really thought doing research would be great is during my final year project at the end of the Bachelor’s degree at UCL. Planning experiments and testing out hypotheses gave me a real thrill and that has not stopped ever since!
X chromosome regulation is among the classical epigenetic phenomena. Understanding how different phenotypes can be generated from a single genome is very interesting as it shows multiple facets as well as complexity underlying regulation impacting on health.
I like the breadth encompassing epigenetics research and hope to provide some contribution in unraveling at least some aspects of this complexity.
I became interested in the phenomenon of dosage compensation during my postdoctoral research in the laboratory of Peter Becker. It was a great time to embark on this project and take a biochemical approach to tackle this problem in fruit flies.
Dosage compensation is an important biological phenomenon. How mere two fold differences can lead to a life or death decision for the organism make it already an extremely interesting biological process to understand.
But, more importantly, it is a great system to study the effects of chromatin based regulation and involvement of long non-coding RNA in epigenetic regulation.
I think it will be really interesting to unravel the mechanisms contributing towards inheritance of epigenetic information to the next generation. Especially studying the diversity at the single-cell level is an extremely exciting prospect for the future.
It’s a great time to work on epigenetics research, many molecules are known but how specificity is achieved remains a mystery. There are also exciting avenues to explore the interplay between the coding and non-coding part of our genome.
Recent technological advances have gained great momentum to study highly complex processes at global and at single gene level. Moreover, epigenetic therapy could provide a great avenue in future to combat disease and contribute to personalized medicine. Therefore, the future is bright for epigenetics research.
Hard to tell! I am not a good housewife!
Outside the lab: My family with two children.
Inside the lab: The excitement of the new unexpected results and trying to make sense of it all with my team.